MNPR vs GSM Comparison

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's operating segments include Canada - Silicon Metals, Canada - Silicon Alloys, U.S. - Silicon Metals, U.S. - Silicon Alloys, Europe - Manganese Alloys, Europe - Silicon Metals, Europe - Silicon Alloys, South Africa - Silicon Metals, South Africa - Silicon Alloys, and Other segments. The primary raw materials the company uses to produce its electrometallurgy products include its coal and quartz mining operations and its silicon metal and ferroalloy production. The firm generates key revenue from Silicon metal and Manganese-based alloys.